CN108464500A - 一种辅助调节高血压的膳食组合物 - Google Patents
一种辅助调节高血压的膳食组合物 Download PDFInfo
- Publication number
- CN108464500A CN108464500A CN201810205347.8A CN201810205347A CN108464500A CN 108464500 A CN108464500 A CN 108464500A CN 201810205347 A CN201810205347 A CN 201810205347A CN 108464500 A CN108464500 A CN 108464500A
- Authority
- CN
- China
- Prior art keywords
- parts
- auxiliary adjustment
- dietary composition
- extract
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 35
- 235000007882 dietary composition Nutrition 0.000 title claims abstract description 29
- 239000000284 extract Substances 0.000 claims abstract description 54
- 239000000843 powder Substances 0.000 claims abstract description 40
- 235000007091 Chlorella pyrenoidosa Nutrition 0.000 claims abstract description 39
- 239000007788 liquid Substances 0.000 claims abstract description 25
- 239000004383 Steviol glycoside Substances 0.000 claims abstract description 15
- 235000019411 steviol glycoside Nutrition 0.000 claims abstract description 15
- 229930182488 steviol glycoside Natural products 0.000 claims abstract description 15
- 150000008144 steviol glycosides Chemical class 0.000 claims abstract description 15
- 235000019202 steviosides Nutrition 0.000 claims abstract description 15
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 13
- 238000004040 coloring Methods 0.000 claims abstract description 13
- 238000000855 fermentation Methods 0.000 claims abstract description 10
- 230000004151 fermentation Effects 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
- 244000249214 Chlorella pyrenoidosa Species 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- 235000019441 ethanol Nutrition 0.000 claims description 35
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 27
- 241001145025 Saussurea involucrata Species 0.000 claims description 22
- 241000233866 Fungi Species 0.000 claims description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 14
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 13
- 239000001569 carbon dioxide Substances 0.000 claims description 13
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 13
- 241000195493 Cryptophyta Species 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000001694 spray drying Methods 0.000 claims description 9
- 229930003944 flavone Natural products 0.000 claims description 8
- 235000011949 flavones Nutrition 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 7
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 7
- 239000001354 calcium citrate Substances 0.000 claims description 7
- 239000004202 carbamide Substances 0.000 claims description 7
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 7
- 239000011790 ferrous sulphate Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 150000002212 flavone derivatives Chemical class 0.000 claims description 7
- 235000001727 glucose Nutrition 0.000 claims description 7
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 7
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 7
- 230000002045 lasting effect Effects 0.000 claims description 7
- 238000009630 liquid culture Methods 0.000 claims description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 7
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 7
- 238000001556 precipitation Methods 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 7
- 238000000108 ultra-filtration Methods 0.000 claims description 7
- 201000002282 venous insufficiency Diseases 0.000 claims description 7
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 7
- 238000009360 aquaculture Methods 0.000 claims description 6
- 244000144974 aquaculture Species 0.000 claims description 6
- 230000036772 blood pressure Effects 0.000 claims description 6
- 239000001488 sodium phosphate Substances 0.000 claims description 6
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 6
- 235000011008 sodium phosphates Nutrition 0.000 claims description 6
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 6
- 206010013786 Dry skin Diseases 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 4
- 241000195649 Chlorella <Chlorellales> Species 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
- 241000190633 Cordyceps Species 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims 1
- 240000002853 Nelumbo nucifera Species 0.000 claims 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 7
- 230000003750 conditioning effect Effects 0.000 abstract description 5
- 238000000605 extraction Methods 0.000 abstract description 5
- 230000006837 decompression Effects 0.000 abstract description 4
- 241000294142 Vascellum Species 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 239000002220 antihypertensive agent Substances 0.000 abstract description 2
- 229940127088 antihypertensive drug Drugs 0.000 abstract description 2
- 230000007812 deficiency Effects 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 238000002955 isolation Methods 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract description 2
- 241000195652 Auxenochlorella pyrenoidosa Species 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 16
- 229960004424 carbon dioxide Drugs 0.000 description 12
- 230000006870 function Effects 0.000 description 8
- 235000013305 food Nutrition 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 235000013877 carbamide Nutrition 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000008399 tap water Substances 0.000 description 6
- 235000020679 tap water Nutrition 0.000 description 6
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 5
- LLJZKKVYXXDWTB-UHFFFAOYSA-N acetic acid;sodium Chemical compound [Na].[Na].CC(O)=O LLJZKKVYXXDWTB-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 235000019197 fats Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108091006146 Channels Proteins 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 241000721047 Danaus plexippus Species 0.000 description 3
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- -1 lignanoid Chemical class 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000005156 Dehydration Diseases 0.000 description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 229940026314 red yeast rice Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- PQMOXTJVIYEOQL-UHFFFAOYSA-N Cumarin Natural products CC(C)=CCC1=C(O)C(C(=O)C(C)CC)=C(O)C2=C1OC(=O)C=C2CCC PQMOXTJVIYEOQL-UHFFFAOYSA-N 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- FSOGIJPGPZWNGO-UHFFFAOYSA-N Meomammein Natural products CCC(C)C(=O)C1=C(O)C(CC=C(C)C)=C(O)C2=C1OC(=O)C=C2CCC FSOGIJPGPZWNGO-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002082 anti-convulsion Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910002090 carbon oxide Inorganic materials 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical group C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229930009674 sesquiterpene lactone Natural products 0.000 description 1
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种辅助调节高血压的膳食组合物。所述辅助调节高血压的膳食组合物按照质量份数包括：天山雪莲提取物20～40份、北虫草提取物20～40份、蛋白核小球藻粉25～45份、红曲粉2～8份和甜菊糖苷0.02～0.1份。本发明以疏通血管、降压、降脂为主，以调和内理、平衡阴阳为辅助，通过现代生物工程液态发酵提取纯化分离技术与传统中医药为相结合，集食疗、预防、调理三重功效于一体，扶正与祛邪并举，标本兼治，极大补充了现有降压药物的不足，且食用方便、便于携带，具有重要的社会和经济效益。
Description
技术领域
本发明涉及食品保健技术领域，具体涉及一种辅助调节高血压的膳食组合物。
背景技术
高血压是最常见的心血管病，是全球范围内的重大公共卫生问题，是指在静息状态下，收缩压和/或舒张压增高(≥140mmHg/90mmHg)，常伴有脂质代谢紊乱及心、脑、肾和视网膜等靶器官功能或器质性变化。
国内外的实践证明，高血压是可控制和能够治疗的慢性非传染性疾病，降低高血压患者的血压水平，可明显减少脑卒中及心脏病事件。常规的治疗是通过降压药物使血液达标，例如：钙通道阻滞剂(CCB)，口服抗凝的华法林、阿司匹林；肾脏保护的利尿药；血管紧张素转换酶抑制剂(ACEI)/血管紧张素受体阻滞剂(ARB)，大多都有一定的副作用，并容易形成依赖性。
“药食同源”是中华原创医学之中对人类最有价值的贡献之一。食疗成为现代人追求返璞归真、健康饮食的最佳选择；以食物为药物具有以下几大突出的优点：一、安全有效，无毒副作用；二、组份为是日常食物或保健品，用餐便可达到调理的目的；三、无痛苦。
本发明将“药食同源”与“新资源食品”的中药相结合，将饮食与养生有机结合，用以调理、预防、抵御高血压。
发明内容
本发明的目的在于提供一种辅助调节高血压的膳食组合物，用膳食调理以减少或替代抗生素的使用，消除传统治疗中的不良反应，达到平稳降压和预防高血压的目的。
为实现上述目的，本发明的技术方案为所述辅助调节高血压的膳食组合物按照质量份数包括：天山雪莲提取物20～40份、北虫草提取物20～40份、蛋白核小球藻粉25～45份、红曲粉2～8份和甜菊糖苷0.02～0.1份。
优选地，所述辅助调节高血压的膳食组合物按照质量份数包括：天山雪莲提取物25～35份、北虫草提取物25～35份、蛋白核小球藻粉30～40份、红曲粉4～6份和甜菊糖苷0.05～0.08份。
优选地，所述辅助调节高血压的膳食组合物按照质量份数包括：天山雪莲提取物30份、北虫草提取物30份、蛋白核小球藻粉35份、红曲粉5份和甜菊糖苷0.07份。
优选地，所述天山雪莲提取物的制备方法包括：
将新鲜天山雪莲花置于链条式烘箱70～80℃低温干燥脱水8～10h，制得含水量8％以下的雪莲干花；将雪莲干花粉碎至80目后置于浓度为80％的乙醇中30min，超滤膜过滤，去除残渣，制得生物黄酮提取原液；60～80℃低温真空浓缩，喷雾干燥制得天山雪莲提取物。
优选地，所述粉碎后的雪莲干花与乙醇质量体积比为1：100。
优选地，所述北虫草提取物的制备方法包括：
将北虫草菌丝体发酵原液在90～100℃条件下水煮2h，6000r/min，离心20min获得上清液，50～70℃的状态下进行浓缩至原体积的15％，转移至95％的乙醇中醇沉6～8h，静置，弃上清得醇沉物，喷雾干燥制得北虫草提取物。
优选地，所述北虫草菌丝体发酵原液的制备方法包括：
无菌条件下，按发酵罐液体培养基体积的8～15％加入北虫草种子液，15～23℃通风比1：0.6～0.8发酵罐内压为0～0.05MPa的条件下连续发酵33～40h，制得北虫草菌丝体发酵原液。
优选地，所述蛋白核小球藻粉的制备方法包括：将蛋白核小球藻藻种接种至养殖池水体中，调节水体pH值至6.5～7.5；加入培养基，植入二氧化碳发生器，20～30℃通入二氧化碳条件下持续光照射5～7天；过滤采集蛋白核小球藻，分离，喷雾干燥后获取蛋白核小球藻粉。
优选地，所述水体为自来水或纯净水；所述培养基为葡萄糖、硫酸镁、柠檬酸钙、磷酸钠、磷酸氢二钾、硫酸亚铁、乙二胺四乙酸二钠和尿素。
本发明所选用中草药的药性及药理如下：
天山雪莲提取物(君药)，味微苦，性温。归肝、脾、肾三经。有温肾助阳，祛风胜湿，通经活血的作用，主要含有的黄酮及其苷、倍半萜内酯、香豆素、木脂素、有机酸、氨基酸、甾体、多糖等成分。现代科学研究证明，天山雪莲含有多种对人体机能的有益成份，能对人体起到极好的调理和保健作用，改善皮肤色素沉着，延缓人体衰老；能有效地调节人体酸碱度，增强人体免疫力及抗疲劳；具有强心作用，对子宫具有强大的选择性兴奋作用，对风湿类风湿及肾虚引起的腰膝酸痛，性功能衰退；具有明显的抗菌、降压、镇静、解痉作用。
北虫草提取物(臣药)，性平，味甘。归肺经、肾经。有补肺益肾、止血，化痰的功效。研究发现虫草含胆固醇、腺苷、麦角固醇、粗蛋白、氨基酸、脂肪、D-甘露醇、冬虫夏草环肽A、半乳甘露聚糖、虫草菌素、虫草酸、麦角甾醇、虫草多糖、生物碱、尿嘧啶、腺嘌呤、腺嘌呤核苷、维生素B12和多种微量元素，具有调节免疫功能，有使免疫功能增强或减弱的双相调节作用；具有较强的抗癌作用；使心率减慢，但心输出量却显著增加；对支气管平滑肌有明显的扩张作用，有平喘和祛痰作用；可使空腹血糖升高；影响内分泌系统，还有抗炎、镇静及抗惊厥作用；具有一定的抗菌作用，能保护肾功能，还具有防辐射、抗突变的作用；能提高细胞吞噬功能，增强心血管和机体免疫机能，还具有抗心律失常等功能。
蛋白核小球藻粉(佐药)，是一种单细胞微藻植物，含有蛋白质50～67％，含有人体所需的20种氨基酸、多种维生素和微量元素，以及亚麻酸、亚油酸、胡萝卜素等成分。其生物素含量为每100克0.18～0.25毫克，参与碳水化合物，蛋白质和脂肪的代谢；叶绿素每100克含量2.4克，参与排出各种毒素；常量元素镁每100克含量243毫克，参与酶的活化，维持血管的收缩和舒张平衡，避免高血压和动脉粥样硬化。研究证明，小球藻细胞糖蛋白具有显著的抑瘤抗癌、增强免疫和抗病毒感染的活性，小球藻所含未知活性因子具有增强细胞代谢、延缓细胞衰老的活性。
红曲粉(使药)，味甘、性温。入肝、脾、大肠经。具有活血化淤、健脾暖胃消食等功效，可用于治产后恶露不净、淤滞腹痛、食积饱胀、赤白下痢、跌打损伤等症。研究发现，红曲中主要作用成分是洛伐他丁，可以降低总胆固醇(TC)，降低低密度脂蛋白胆固醇(LDL-C)，降低甘油三酯(TG)，同时提高高密度脂蛋白(HDL-C)，起到降血压、降血脂的作用。
甜菊糖苷，是一类从甜叶菊叶子中提取的高甜度、低热值的甜味剂，是一种非常理想的蔗糖替代品。毒理学实验表明，甜菊糖苷不仅安全，而且在食品领域有着广阔的应用。此外，甜菊糖苷还表现出许多功能活性，如降血压、降血糖、抗肿瘤、抑菌、抗腹泻、增溶等功能。
本发明方法具有如下优点：
1、本发明的辅助调节高血压的膳食组合物，以温肾助阳、调和内理的雪莲为君药，用以疏通血管；以阴阳调和、降压降脂的北虫草为臣药；以抑制脂肪吸收、促进高脂肪食品排出的蛋白核小球藻为佐药，用以辅助降压、降脂；以降血压、降血脂红曲为使药，配合甜菊糖苷，用以降压、降脂，扶正与祛邪并举，“君臣佐使”共进互凑，既能有效疏通血管，又能达到综合降压的目的，治标与治本同施。
2、本发明的辅助调节高血压的膳食组合物，同时根据高血压体质特征，添加天然、原生态的多种药食同源食材，集食疗、预防、调理三重功效于一体。
3、本发明通过天然中草药合理配伍，具有无毒副作用，无抗药性的特点，制备过程利用现代生物工程液态发酵提取纯化分离技术，使得药材中的有效成分充分释放，可以抵消抗生素类药物带来的不良反应，或替代抗生素类药物，防治效果好，安全性强，平稳降压。
4、本发明的辅助调节高血压的膳食组合物，食用方便、便于携带，口感好，效果佳，防治兼用，适合中国大众防治高血压需求。
具体实施方式
以下实施例用于说明本发明，但不用来限制本发明的范围。
实施例1
本实施例的辅助调节高血压的膳食组合物，按以下步骤制备：
天山雪莲提取物：将500g新鲜天山雪莲花置于链条式烘箱75℃低温干燥脱水9h，制得含水量8％以下的雪莲干花；将雪莲干花粉碎至80目后置于浓度为80％的乙醇中(雪莲干花与乙醇质量体积比为1：100)放置30min，超滤膜过滤，去除残渣，制得生物黄酮提取原液；70℃低温真空浓缩，喷雾干燥制得天山雪莲提取物。
北虫草提取物：无菌条件下，按发酵罐液体培养基体积的12％加入北虫草种子液，18℃通风比1：0.7发酵罐内压为0.03MPa的条件下连续发酵33h，制得北虫草菌丝体发酵原液。
将10g北虫草菌丝体发酵原液在94℃条件下水煮2h，6000r/min，离心20min获得上清液，68℃的状态下进行浓缩至原体积的15％，转移至95％的乙醇中醇沉7h，静置，弃上清得醇沉物，喷雾干燥制得北虫草提取物。
蛋白核小球藻粉：将30g蛋白核小球藻藻种接种至养殖池自来水或纯净水中，调节水体pH值至6.8；加入葡萄糖、硫酸镁、柠檬酸钙、磷酸钠、磷酸氢二钾、硫酸亚铁、乙二胺四乙酸二钠和尿素，植入二氧化碳发生器，28℃通入二氧化碳条件下持续光照射6天；过滤采集蛋白核小球藻，分离，喷雾干燥后获取蛋白核小球藻粉。
然后，将天山雪莲提取物30份、北虫草提取物30份、蛋白核小球藻粉35份、红曲粉5份和甜菊糖苷0.07份充分混匀，按照GB/T29602进行封装，每袋10g，置于常温、避光、干燥处保存，保质期常温下24个月。食用方法：每日两包，热水冲服，饭前食用。
实施例2
本实施例的辅助调节高血压的膳食组合物，按以下步骤制备：
天山雪莲提取物：将400g新鲜天山雪莲花置于链条式烘箱80℃低温干燥脱水8h，制得含水量8％以下的雪莲干花；将雪莲干花粉碎至80目后置于浓度为80％的乙醇中(雪莲干花与乙醇质量体积比为1：100)放置30min，超滤膜过滤，去除残渣，制得生物黄酮提取原液；65℃低温真空浓缩，喷雾干燥制得天山雪莲提取物。
北虫草提取物：无菌条件下，按发酵罐液体培养基体积的15％加入北虫草种子液，15℃通风比1：0.6发酵罐内压为0.05MPa的条件下连续发酵39h，制得北虫草菌丝体发酵原液。
将25g北虫草菌丝体发酵原液在98℃条件下水煮2h，6000r/min，离心20min获得上清液，55℃的状态下进行浓缩至原体积的15％，转移至95％的乙醇中醇沉6h，静置，弃上清得醇沉物，喷雾干燥制得北虫草提取物。
蛋白核小球藻粉：将25g蛋白核小球藻藻种接种至养殖池自来水或纯净水中，调节水体pH值至7.5；加入葡萄糖、硫酸镁、柠檬酸钙、磷酸钠、磷酸氢二钾、硫酸亚铁、乙二胺四乙酸二钠和尿素，植入二氧化碳发生器，22℃通入二氧化碳条件下持续光照射5天；过滤采集蛋白核小球藻，分离，喷雾干燥后获取蛋白核小球藻粉。
然后，将天山雪莲提取物35份、北虫草提取物40份、蛋白核小球藻粉30份、红曲粉4份和甜菊糖苷0.02份充分混匀，按照GB/T29602进行封装，每袋10g，置于常温、避光、干燥处保存，保质期常温下24个月。食用方法：每日两包，热水冲服，饭前食用。
实施例3
本实施例的辅助调节高血压的膳食组合物，按以下步骤制备：
天山雪莲提取物：将600g新鲜天山雪莲花置于链条式烘箱70℃低温干燥脱水8.5h，制得含水量8％以下的雪莲干花；将雪莲干花粉碎至80目后置于浓度为80％的乙醇中(雪莲干花与乙醇质量体积比为1：100)放置30min，超滤膜过滤，去除残渣，制得生物黄酮提取原液；77℃低温真空浓缩，喷雾干燥制得天山雪莲提取物。
北虫草提取物：无菌条件下，按发酵罐液体培养基体积的9％加入北虫草种子液，23℃通风比1：0.8发酵罐内压为0.02MPa的条件下连续发酵37h，制得北虫草菌丝体发酵原液。
将18g北虫草菌丝体发酵原液在100℃条件下水煮2h，6000r/min，离心20min获得上清液，50℃的状态下进行浓缩至原体积的15％，转移至95％的乙醇中醇沉8h，静置，弃上清得醇沉物，喷雾干燥制得北虫草提取物。
蛋白核小球藻粉：将22g蛋白核小球藻藻种接种至养殖池自来水或纯净水中，调节水体pH值至6.5；加入葡萄糖、硫酸镁、柠檬酸钙、磷酸钠、磷酸氢二钾、硫酸亚铁、乙二胺四乙酸二钠和尿素，植入二氧化碳发生器，20℃通入二氧化碳条件下持续光照射6天；过滤采集蛋白核小球藻，分离，喷雾干燥后获取蛋白核小球藻粉。
然后，将天山雪莲提取物20份、北虫草提取物35份、蛋白核小球藻粉25份、红曲粉8份和甜菊糖苷0.1份充分混匀，按照GB/T29602进行封装，每袋10g，置于常温、避光、干燥处保存，保质期常温下24个月。食用方法：每日两包，热水冲服，饭前食用。
实施例4
本实施例的辅助调节高血压的膳食组合物，按以下步骤制备：
天山雪莲提取物：将800g新鲜天山雪莲花置于链条式烘箱72℃低温干燥脱水10h，制得含水量8％以下的雪莲干花；将雪莲干花粉碎至80目后置于浓度为80％的乙醇中(雪莲干花与乙醇质量体积比为1：100)放置30min，超滤膜过滤，去除残渣，制得生物黄酮提取原液；78℃低温真空浓缩，喷雾干燥制得天山雪莲提取物。
北虫草提取物：无菌条件下，按发酵罐液体培养基体积的8％加入北虫草种子液，22℃通风比1：0.7发酵罐内压为0.01MPa的条件下连续发酵35h，制得北虫草菌丝体发酵原液。
将33g北虫草菌丝体发酵原液在90℃条件下水煮2h，6000r/min，离心20min获得上清液，70℃的状态下进行浓缩至原体积的15％，转移至95％的乙醇中醇沉6h，静置，弃上清得醇沉物，喷雾干燥制得北虫草提取物。
蛋白核小球藻粉：将8g蛋白核小球藻藻种接种至养殖池自来水或纯净水中，调节水体pH值至7.2；加入葡萄糖、硫酸镁、柠檬酸钙、磷酸钠、磷酸氢二钾、硫酸亚铁、乙二胺四乙酸二钠和尿素，植入二氧化碳发生器，30℃通入二氧化碳条件下持续光照射7天；过滤采集蛋白核小球藻，分离，喷雾干燥后获取蛋白核小球藻粉。
然后，将天山雪莲提取物25份、北虫草提取物20份、蛋白核小球藻粉45份、红曲粉6份和甜菊糖苷0.08份充分混匀，按照GB/T29602进行封装，每袋10g，置于常温、避光、干燥处保存，保质期常温下24个月。食用方法：每日两包，热水冲服，饭前食用。
实施例5
本实施例的辅助调节高血压的膳食组合物，按以下步骤制备：
天山雪莲提取物：将450g新鲜天山雪莲花置于链条式烘箱74℃低温干燥脱水9.5h，制得含水量8％以下的雪莲干花；将雪莲干花粉碎至80目后置于浓度为80％的乙醇中(雪莲干花与乙醇质量体积比为1：100)放置30min，超滤膜过滤，去除残渣，制得生物黄酮提取原液；66℃低温真空浓缩，喷雾干燥制得天山雪莲提取物。
北虫草提取物：无菌条件下，按发酵罐液体培养基体积的14％加入北虫草种子液，16℃通风比1：0.6发酵罐内压为0.05MPa的条件下连续发酵40h，制得北虫草菌丝体发酵原液。
将40g北虫草菌丝体发酵原液在99℃条件下水煮2h，6000r/min，离心20min获得上清液，65℃的状态下进行浓缩至原体积的15％，转移至95％的乙醇中醇沉7.5h，静置，弃上清得醇沉物，喷雾干燥制得北虫草提取物。
蛋白核小球藻粉：将20g蛋白核小球藻藻种接种至养殖池自来水或纯净水中，调节水体pH值至7.4；加入葡萄糖、硫酸镁、柠檬酸钙、磷酸钠、磷酸氢二钾、硫酸亚铁、乙二胺四乙酸二钠和尿素，植入二氧化碳发生器，28℃通入二氧化碳条件下持续光照射6天；过滤采集蛋白核小球藻，分离，喷雾干燥后获取蛋白核小球藻粉。
然后，将天山雪莲提取物25份、北虫草提取物25份、蛋白核小球藻粉40份、红曲粉2份和甜菊糖苷0.02份充分混匀，按照GB/T29602进行封装，每袋10g，置于常温、避光、干燥处保存，保质期常温下24个月。食用方法：每日两包，热水冲服，饭前食用。
虽然，上文中已经用一般性说明及具体实施例对本发明作了详尽的描述，但在本发明基础上，可以对之作一些修改或改进，这对本领域技术人员而言是显而易见的。因此，在不偏离本发明精神的基础上所做的这些修改或改进，均属于本发明要求保护的范围。
Claims (9)
1.一种辅助调节高血压的膳食组合物，其特征在于：所述辅助调节高血压的膳食组合物按照质量份数包括：天山雪莲提取物20～40份、北虫草提取物20～40份、蛋白核小球藻粉25～45份、红曲粉2～8份和甜菊糖苷0.02～0.1份。
2.根据权利要求1所述的辅助调节高血压的膳食组合物，其特征在于：所述辅助调节高血压的膳食组合物按照质量份数包括：天山雪莲提取物25～35份、北虫草提取物25～35份、蛋白核小球藻粉30～40份、红曲粉4～6份和甜菊糖苷0.05～0.08份。
3.根据权利要求2所述的辅助调节高血压的膳食组合物，其特征在于：所述辅助调节高血压的膳食组合物按照质量份数包括：天山雪莲提取物30份、北虫草提取物30份、蛋白核小球藻粉35份、红曲粉5份和甜菊糖苷0.07份。
4.根据权利要求1-3任一项所述的辅助调节高血压的膳食组合物，其特征在于：所述天山雪莲提取物的制备方法包括：
将新鲜天山雪莲花置于链条式烘箱70～80℃低温干燥脱水8～10h，制得含水量8％以下的雪莲干花；将雪莲干花粉碎至80目后置于浓度为80％的乙醇中30min，超滤膜过滤，去除残渣，制得生物黄酮提取原液；60～80℃低温真空浓缩，喷雾干燥制得天山雪莲提取物。
5.根据权利要求4所述的辅助调节高血压的膳食组合物，其特征在于：所述粉碎后的雪莲干花与乙醇质量体积比为1：100。
6.根据权利要求1-3任一项所述的辅助调节高血压的膳食组合物，其特征在于：所述北虫草提取物的制备方法包括：
将北虫草菌丝体发酵原液在90～100℃条件下水煮2h，6000r/min，离心20min获得上清液，50～70℃的状态下进行浓缩至原体积的15％，转移至95％的乙醇中醇沉6～8h，静置，弃上清得醇沉物，喷雾干燥制得北虫草提取物。
7.根据权利要求6所述的辅助调节高血压的膳食组合物，其特征在于：所述北虫草菌丝体发酵原液的制备方法包括：
无菌条件下，按发酵罐液体培养基体积的8～15％加入北虫草种子液，15～23℃通风比1：0.6～0.8发酵罐内压为0～0.05MPa的条件下连续发酵33～40h，制得北虫草菌丝体发酵原液。
8.根据权利要求1-3任一项所述的辅助调节高血压的膳食组合物，其特征在于：所述蛋白核小球藻粉的制备方法包括：将蛋白核小球藻藻种接种至养殖池水体中，调节水体pH值至6.5～7.5；加入培养基，植入二氧化碳发生器，20～30℃通入二氧化碳条件下持续光照射5～7天；过滤采集蛋白核小球藻，分离，喷雾干燥后获取蛋白核小球藻粉。
9.根据权利要求8所述的辅助调节高血压的膳食组合物，其特征在于：所述水体为自来水或纯净水；所述培养基为葡萄糖、硫酸镁、柠檬酸钙、磷酸钠、磷酸氢二钾、硫酸亚铁、乙二胺四乙酸二钠和尿素。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810205347.8A CN108464500A (zh) | 2018-03-13 | 2018-03-13 | 一种辅助调节高血压的膳食组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810205347.8A CN108464500A (zh) | 2018-03-13 | 2018-03-13 | 一种辅助调节高血压的膳食组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108464500A true CN108464500A (zh) | 2018-08-31 |
Family
ID=63265281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810205347.8A Pending CN108464500A (zh) | 2018-03-13 | 2018-03-13 | 一种辅助调节高血压的膳食组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108464500A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022013888A1 (en) * | 2020-07-16 | 2022-01-20 | Nbi Biosciences Private Limited | Anti-hypercholesterolemia composition and a method of manufacturing the same |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634546A (zh) * | 2004-10-31 | 2005-07-06 | 青海石油管理局 | 螺旋藻及其提取物与中藏药配伍的保健食品 |
| CN101926842A (zh) * | 2010-09-07 | 2010-12-29 | 郭景龙 | 一种原料含有雪莲和发酵虫草菌粉的药物组合物 |
| TWM471274U (zh) * | 2013-07-05 | 2014-02-01 | Tci Co Ltd | 預防與改善肝病、降三高、瘦身、祛寒及美化膚質的雪蓮萃取微粒之包裝結構 |
| CN105343145A (zh) * | 2015-12-14 | 2016-02-24 | 梁文成 | 一种雪莲虫草含片及其制作方法 |
| CN106943464A (zh) * | 2017-03-08 | 2017-07-14 | 辽宁环健生物科技有限公司 | 一种调节高血压的生物营养配方组合物 |
| CN107006840A (zh) * | 2017-02-23 | 2017-08-04 | 北京众康生物科技有限公司 | 一种雪莲培养物胶囊及其制备方法 |
| CN107095300A (zh) * | 2017-03-08 | 2017-08-29 | 辽宁山水源植物科技有限公司 | 一种辅助治疗糖尿病的生物营养配方组合物 |
-
2018
- 2018-03-13 CN CN201810205347.8A patent/CN108464500A/zh active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634546A (zh) * | 2004-10-31 | 2005-07-06 | 青海石油管理局 | 螺旋藻及其提取物与中藏药配伍的保健食品 |
| CN101926842A (zh) * | 2010-09-07 | 2010-12-29 | 郭景龙 | 一种原料含有雪莲和发酵虫草菌粉的药物组合物 |
| TWM471274U (zh) * | 2013-07-05 | 2014-02-01 | Tci Co Ltd | 預防與改善肝病、降三高、瘦身、祛寒及美化膚質的雪蓮萃取微粒之包裝結構 |
| CN105343145A (zh) * | 2015-12-14 | 2016-02-24 | 梁文成 | 一种雪莲虫草含片及其制作方法 |
| CN107006840A (zh) * | 2017-02-23 | 2017-08-04 | 北京众康生物科技有限公司 | 一种雪莲培养物胶囊及其制备方法 |
| CN106943464A (zh) * | 2017-03-08 | 2017-07-14 | 辽宁环健生物科技有限公司 | 一种调节高血压的生物营养配方组合物 |
| CN107095300A (zh) * | 2017-03-08 | 2017-08-29 | 辽宁山水源植物科技有限公司 | 一种辅助治疗糖尿病的生物营养配方组合物 |
Non-Patent Citations (7)
| Title |
|---|
| 刘玉田等: "《藻类食品新工艺与新配方》", 30 June 2002, 山东科学技术出版社 * |
| 刘程: "《食品添加剂实用大全》", 31 January 2004, 北京工业大学出版社 * |
| 姜性坚: "《药用菌栽培新技术》", 31 March 2012, 湖南科学技术出版社 * |
| 孙明等: "红曲降血压作用的研究 ", 《卫生研究》 * |
| 桂镜生: "《中药商品学》", 31 August 2015, 云南大学出版社 * |
| 王向东等: "《发酵食品工艺学》", 31 January 2011, 中国计量出版社 * |
| 黄世敬等: "《中药临床合理应用手册》", 30 April 2009, 金盾出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022013888A1 (en) * | 2020-07-16 | 2022-01-20 | Nbi Biosciences Private Limited | Anti-hypercholesterolemia composition and a method of manufacturing the same |
| EP4181939A4 (en) * | 2020-07-16 | 2024-07-31 | Nbi Biosciences Private Ltd | ANTI-HYPERCHOLESTEROLEMIA COMPOSITION AND METHOD OF MANUFACTURING SAME |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103039671B (zh) | 虫草速溶茶 | |
| CN104087488B (zh) | 一种树莓复合果酒及其酿造方法 | |
| CN103740566B (zh) | 一种刺梨药酒及其制作方法 | |
| CN106072578A (zh) | 具有增强人体免疫功能的酵素组合物、泡腾片及制法 | |
| CN101603010A (zh) | 一种肉灵芝快速培育方法 | |
| CN103462022B (zh) | 北冬虫夏草滋补膏及其制备方法 | |
| CN112137079A (zh) | 利用酒曲发酵工艺的健康食品组合物及其制造方法 | |
| CN109601795A (zh) | 以赶黄草为主要原料的组合物解酒饮料及其制备方法 | |
| CN104906361A (zh) | 一种降血脂黄酒及其制作方法 | |
| CN109528814A (zh) | 一种乳酸菌发酵黄芪的微生态制剂及其制备方法和应用 | |
| CN103301321B (zh) | 一种溶栓活性多糖合剂的制作工艺 | |
| CN110810693A (zh) | 一种含有显齿蛇葡萄的饮料组合物及其制备方法 | |
| CN103829249A (zh) | 一种调理脾胃湿热体质酵素及其制备方法 | |
| CN104382127B (zh) | 一种黑蒜蜂蜜醋饮料 | |
| CN110075266A (zh) | 一种养肾固肾补气血的配方及制备方法 | |
| CN108464500A (zh) | 一种辅助调节高血压的膳食组合物 | |
| CN106924548A (zh) | 一种缓解疲劳的药物及制备方法 | |
| CN106434227A (zh) | 一种抗疲劳的玛咖酒及其制备方法 | |
| CN106666703A (zh) | 具有保肝护肝功效的酵素组合物、制剂及制备方法 | |
| CN105713787B (zh) | 一种护肝型藏红花葛根黄酒的制备方法 | |
| CN103478706B (zh) | 一种天然葛酵素及其制法 | |
| CN109497388A (zh) | 一种心脑血管疾病的预防和辅助的药物 | |
| CN109275751A (zh) | 杜仲叶降压茶及其制备方法 | |
| CN101496604A (zh) | 一种具有降血脂功能的营养食品及其制备方法 | |
| CN113652461A (zh) | 一种黄精植物甾醇多糖蛋白的制备方法及其活性制品 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180831 |
|
| RJ01 | Rejection of invention patent application after publication |